Targeting Tumor-Rejection Antigens in Melanoma With Tumor-Infiltrating Lymphocytes
- PMID: 34086482
- PMCID: PMC8376378
- DOI: 10.1200/JCO.21.01012
Targeting Tumor-Rejection Antigens in Melanoma With Tumor-Infiltrating Lymphocytes
Conflict of interest statement
Comment on
-
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.J Clin Oncol. 2021 Aug 20;39(24):2656-2666. doi: 10.1200/JCO.21.00612. Epub 2021 May 12. J Clin Oncol. 2021. PMID: 33979178 Free PMC article.
References
-
- Prehn RT, Main JM: Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 18:769-778, 1957 - PubMed
-
- Foley E: Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res 13:835-837, 1953 - PubMed
-
- Srivastava PK: Immunotherapy for human cancer using heat shock protein-peptide complexes. Curr Oncol Rep 7:104-108, 2005 - PubMed
-
- Lammert E, Arnold D, Nijenhuis M, et al. : The endoplasmic reticulum-resident stress protein gp96 binds peptides translocated by TAP. Eur J Immunol 27:923-927, 1997 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
